1 minute read
EpiPens fully funded from 1st Feb
by WBOP PHO
Epipen: What people need to know - Pharmac | New Zealand Government
Victoza® (liraglutide injection) now funded for people with type 2 diabetes
From 1st March 2023, Victoza® (liraglutide injection) will be funded by Pharmac for patients with type 2 diabetes who meet the current eligibility criteria for GLP-1 receptor agonists.
An alternative to Trulicity for those who would benefit from GLP-1 receptor antagonists.
Research Request: COVID's impact on Respiratory Presentations
Invitation to participate sent to Practice Managers on February 20.
The research will provide an accurate picture of the incidence of respiratory infection presenting through general practice over the last ten years, and in particular, explore the impact of COVID-19 on the presentations to General Practice.
Practices will be asked to participate in one or two phases of the study. Phase 1 involves the capture of a small set of deidentified clinical notes from consenting practices.
Contact is Rachel Blanch Rachel@datacraft.nz
